Momelotinib

(Ojjaara)

Momelotinib

Drug updated on 11/17/2023

Dosage FormTablet (oral; 100 mg, 150 mg, 200 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

Product Monograph / Prescribing Information

Document TitleYearSource
Ojjaara (momelotinib) Prescribing Information.2023GlaxoSmithKline LLC, Philadelphia, PA

Systematic Reviews / Meta-Analyses